Abstract：
OBJECTIVE: There are currently 11 antibody-drug conjugates (ADC) that are FDA approved for use in oncologic disease states, with many more in the pipeline. The authors aim to review the pharmacokinetic profiles of the components of ADCs to engage pharmacist practitioners in practical considerations in the care of patients. This article provides an overview on the use of ADCs in the setting of organ dysfunction, drug-drug interactions, and management of on- and off-target adverse effects.
METHODS: A systematic search of the literature on ADCs through September 2023 was conducted. Clinical trials as well as articles on ADC design and functional components, adverse effects, and pharmacokinetics were reviewed. Reviewed literature included prescribing information as well as tertiary sources and primary literature.
METHODS: A total of 11 ADCs were reviewed for the purpose of this article. A description of the mechanism of action and structure of ADCs is outlined, and a table containing description of each currently FDA-approved ADC is included. Various mechanisms of ADC toxicity are reviewed, including how ADC structure may be implicated.
CONCLUSIONS: It is imperative that pharmacist clinicians understand the design and function of each component of an ADC to continue to assess new approvals for use in oncology patients. Understanding the design of the ADC can help a pharmacy practitioner compare and contrast adverse effect profiles to support their multidisciplinary teams and to engage patients in education and management of their care.
METHODS: A systematic search of the literature on ADCs through September 2023 was conducted. Clinical trials as well as articles on ADC design and functional components, adverse effects, and pharmacokinetics were reviewed. Reviewed literature included prescribing information as well as tertiary sources and primary literature.
METHODS: A total of 11 ADCs were reviewed for the purpose of this article. A description of the mechanism of action and structure of ADCs is outlined, and a table containing description of each currently FDA-approved ADC is included. Various mechanisms of ADC toxicity are reviewed, including how ADC structure may be implicated.
CONCLUSIONS: It is imperative that pharmacist clinicians understand the design and function of each component of an ADC to continue to assess new approvals for use in oncology patients. Understanding the design of the ADC can help a pharmacy practitioner compare and contrast adverse effect profiles to support their multidisciplinary teams and to engage patients in education and management of their care.
摘要：
目的：目前有11种抗体-药物偶联物（ADC）被FDA批准用于肿瘤疾病状态，还有更多的在管道中。作者旨在回顾ADC成分的药代动力学特征，以使药剂师从业者参与患者护理的实际考虑。本文概述了ADC在器官功能障碍中的应用，药物-药物相互作用，以及目标上和目标外不良反应的管理。
方法：对截至2023年9月的ADC文献进行了系统搜索。临床试验以及有关ADC设计和功能组件的文章，不利影响，和药代动力学进行了综述。审查的文献包括处方信息以及第三来源和主要文献。
方法：为本文的目的，共审查了11个ADC。概述了ADC的作用机制和结构的描述，包括包含每个当前FDA批准的ADC的描述的表格。本文综述了ADC毒性的各种机制。包括ADC结构如何被牵连。
结论：药剂师必须了解ADC的每个组件的设计和功能，以继续评估用于肿瘤学患者的新批准。了解ADC的设计可以帮助药房从业者比较和对比不良反应概况，以支持他们的多学科团队，并让患者参与他们的护理教育和管理。
方法：对截至2023年9月的ADC文献进行了系统搜索。临床试验以及有关ADC设计和功能组件的文章，不利影响，和药代动力学进行了综述。审查的文献包括处方信息以及第三来源和主要文献。
方法：为本文的目的，共审查了11个ADC。概述了ADC的作用机制和结构的描述，包括包含每个当前FDA批准的ADC的描述的表格。本文综述了ADC毒性的各种机制。包括ADC结构如何被牵连。
结论：药剂师必须了解ADC的每个组件的设计和功能，以继续评估用于肿瘤学患者的新批准。了解ADC的设计可以帮助药房从业者比较和对比不良反应概况，以支持他们的多学科团队，并让患者参与他们的护理教育和管理。
